US equities |
NVDA $239.78 ▲+2.49% SPCX $169.49 ▲+6.62% MU $1,060.40 ▼-1.35% TSLA $380.83 ▲+2.76% SNDK $1,691.60 ▼-1.65% MSFT $528.51 ▲+2.12% INTC $116.38 ▼-2.47% META $743.37 ▲+2.10%
FinancialContent

Autolus Therapeutics plc - American Depositary Shares (NQ:AUTL)

1.840 +0.060 (+3.37%)
Delayed Quote Updated: 3:17 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Autolus Therapeutics plc - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
AUTL Stock Earnings: Autolus Therapeutics Misses EPS for Q2 2024 ↗
AUTL stock results show that Autolus Therapeutics missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
Autolus Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
A Glimpse Into The Expert Outlook On Autolus Therapeutics Through 5 Analysts ↗
 
Via Benzinga
News headline image
Breaking Down Autolus Therapeutics: 4 Analysts Share Their Views ↗
 
Via Benzinga
News headline image
Autolus Therapeutics's Earnings Outlook ↗
 
Via Benzinga
News headline image
Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Stocks to Buy: 3 Biotech Bargains Delivering Breakthroughs on a Budget ↗
Since wealth without health is utterly meaningless, investors may have some confidence with these biotech stocks to buy. 
Via InvestorPlace
News headline image
Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL in an oral presentation at ASCO
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Crude Oil Gains 1%; GameStop Shares Plunge ↗
 
Via Benzinga
News headline image
Why Cracker Barrel Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
 
Via Benzinga
News headline image
AUTL Stock Earnings: Autolus Therapeutics Misses EPS, Misses Revenue for Q1 2024 ↗
AUTL stock results show that Autolus Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Despegar.com Posts Strong Sales, Joins Reddit, Robinhood And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
News headline image
Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics Announces Delay to its First Quarter 2024 Earnings Release and Conference Call
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics Announces Changes to its Board of Directors
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics announces publication in Blood Cancer Journal
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Earnings Scheduled For March 14, 2024 ↗
Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for its fourth quarter. 
Via Benzinga
News headline image
Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics announces publication in Nature Communications
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Announces Pricing of Underwritten Offering
From Autolus Therapeutics plc
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >